Complete protein sequence and identification of structural domains of human apolipoprotein B

Epidemiological, pathological and genetic studies show a strong positive correlation between elevated plasma concentrations of low-density lipoprotein (LDL) cholesterol and the risk of premature coronary heart disease1–3. Apolipoprotein (apo) B-100 is the sole protein component of LDL and is the ligand responsible for the receptor-mediated uptake and clearance of LDL from the circulation2–6. Apo B-100 is made by the liver and is essential for the assembly of triglyceride-rich very low-density lipoproteins (VLDL) in the cisternae of the endoplasmic reticulum and for their secretion into the plasma. VLDL transports triglyceride to peripheral muscle and adipose tissue, where the triglyceride is hydrolysed by lipoprotein lipase. The resultant particle, relatively enriched in cholesteryl ester, constitutes LDL. LDL delivers cholesterol to peripheral tissues where it is used for membrane and steroid hormone biosynthesis and to the liver, the only organ which can catabolize and excrete cholesterol. Plasma LDL levels are therefore determined by the balance between their rate of production from VLDL and clearance by the hepatic LDL (apo B/E) receptor pathway. Here we report the complete 4,563-amino-acid sequence of apo B-100 precursor (relative molecular mass (Mr) 514,000 (514K)) determined from complementary DNA clones. Numerous lipid-binding structures are distributed throughout the extraordinary length of apo B-100 and must underlie its special functions as a nucleus for lipoprotein assembly and maintenance of plasma lipoprotein integrity. A domain enriched in basic amino-acid residues has been identified as important for the cellular uptake of cholesterol by the LDL receptor pathway.

[1]  R. Krauss,et al.  Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses. , 1985, The Journal of biological chemistry.

[2]  V. Schumaker,et al.  Molecular weights of apoprotein B obtained from human low-density lipoprotein (apoprotein B-PI) and from rat very low density lipoprotein (apoprotein B-PIII). , 1985, Biochemistry.

[3]  J. Lee,et al.  High-level expression of M13 gene II protein from an inducible polycistronic messenger RNA. , 1985, Gene.

[4]  R. Mahley,et al.  Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. , 1984, The Journal of biological chemistry.

[5]  J. Kane,et al.  Scission of human apolipoprotein B-100 by kallikrein: characterization of the cleavage site. , 1986, Biochemical and biophysical research communications.

[6]  R. Jackson,et al.  Sulfhydryl chemistry and solubility properties of human plasma apolipoprotein B. , 1982, Biochemistry.

[7]  W. C. Breckenridge,et al.  The carbohydrate composition of human apo low density lipoprotein from normal and type II hyperlipoproteinemic subjects. , 1976, Canadian journal of biochemistry.

[8]  R. Mahley,et al.  The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. , 1983, The Journal of biological chemistry.

[9]  M. Lane,et al.  Association and assembly of triglyceride and phospholipid with glycosylated and unglycosylated apoproteins of very low density lipoprotein in the intact liver cell. , 1982, The Journal of biological chemistry.

[10]  V. Schumaker,et al.  Human apolipoprotein B: partial amino acid sequence , 1984, FEBS letters.

[11]  H. Rauvala,et al.  High-mannose structure of apolipoprotein-B from low-density lipoproteins of human plasma. , 1985, European journal of biochemistry.

[12]  D. Eisenberg,et al.  Analysis of membrane and surface protein sequences with the hydrophobic moment plot. , 1984, Journal of molecular biology.

[13]  N. Christensen,et al.  Ultrastructural immunolocalization of apolipoprotein B within human jejunal absorptive cells. , 1983, Journal of lipid research.

[14]  Russell F. Doolittle,et al.  The genealogy of some recently evolved vertebrate proteins , 1985 .

[15]  J. Breslow.  Human apolipoprotein molecular biology and genetic variation. , 1985, Annual review of biochemistry.

[16]  M. Oliver.  Prevention of coronary heart disease--propaganda, promises, problems, and prospects. , 1986, Circulation.

[17]  A. Gotto,et al.  A molecular theory of lipid—protein interactions in the plasma lipoproteins , 1974, FEBS letters.

[18]  L. Rosenberg,et al.  Metabolic control and disease , 1980 .

[19]  E. Kaiser,et al.  Amphiphilic secondary structure: design of peptide hormones. , 1984, Science.

[20]  E. Kaiser,et al.  A SYNTHETIC AMPHIPHILIC β-STRAND TRIDECAPEPTIDE: A MODEL FOR APOLIPOPROTEIN B , 1984 .

[21]  R. Mahley,et al.  Plasma lipoproteins: apolipoprotein structure and function. , 1984, Journal of lipid research.

[22]  D. Russell,et al.  Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. , 1986, Science.

[23]  W. N. Burnette,et al.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. , 1981, Analytical biochemistry.

[24]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[25]  W. Rutter,et al.  Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin , 1985, Nature.

[26]  K. Belt,et al.  The structural basis of the multiple forms of human complement component C4 , 1984, Cell.

[27]  F. V. van’t Hooft,et al.  Metabolism of chromatographically separated rat serum lipoproteins specifically labeled with 125I-apolipoprotein E. , 1981, The Journal of biological chemistry.

[28]  G. Shipley,et al.  Structure and interactions of lipids in human plasma low density lipoproteins. , 1977, The Journal of biological chemistry.

[29]  P. Y. Chou,et al.  Empirical predictions of protein conformation. , 1978, Annual review of biochemistry.

[30]  R. Freedman.  Native disulphide bond formation in protein biosynthesis: evidence for the role of protein disulphide isomerase , 1984 .

[31]  J. Kane.  Apolipoprotein B: structural and metabolic heterogeneity. , 1983, Annual review of physiology.

[32]  R. Eddy,et al.  Human apolipoprotein B: structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization. , 1985, Science.

[33]  R. Mahley,et al.  The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. , 1983, The Journal of biological chemistry.

[34]  S. Young,et al.  Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Young,et al.  Conservation of the Low Density Lipoprotein Receptor‐Binding Domain of Apoprotein B , 1986, Arteriosclerosis.

[36]  T. Südhof,et al.  Cassette of eight exons shared by genes for LDL receptor and EGF precursor. , 1985, Science.

[37]  K. Berg,et al.  Antibodies to inherited &‐lipoprotein antigens in the serum of multiply transfused patients , 1970 .

[38]  B. Müller-Hill,et al.  Easy identification of cDNA clones. , 1983, The EMBO journal.

[39]  Y. Marcel,et al.  Mapping of antigenic determinants of human apolipoprotein B using monoclonal antibodies against low density lipoproteins. , 1982, The Journal of biological chemistry.

[40]  J. Kane,et al.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. , 1980, Proceedings of the National Academy of Sciences of the United States of America.